Pro-arrhythmogenic effect of lappaconitine hydrobromide

The article presents a clinical case of the development of the pro-arrhythmogenic effect of lappaconitine hydrobromide in the form of monomorphic ventricular tachycardia in a 68-year-old female patient. Upon admission, there were complaints of a constant feeling of heaviness in the sternum and shortness of breath, episodes of dizziness and unsteadiness when walking, interruptions in the work of the heart, occurring with minor physical exertion. The patient has a history of type 2 myocardial infarction (two years ago), during inpatient treatment ventricular tachycardia was recorded, due to which amiodarone was prescribed. At the outpatient stage, amiodarone was replaced with lappaconitine hydrobromide. Three days before the current hospitalization, during Holter ECG monitoring, frequent ventricular extrasystoles, episodes of unstable and stable ventricular monomorphic tachycardia were recorded. The detected arrhythmia was assessed as a proarrhythmogenic effect of lappaconitine hydrobromide, due to which this drug was discontinued and amiodarone was prescribed. During echocardiography on the second day of hospitalization, diffuse myocardial hypokinesia was detected, a decrease in the left ventricular ejection fraction to 48%. During the treatment, an improvement in well-being was noted: chest discomfort, shortness of breath, and attacks of palpitations did not bother. One month after hospitalization, outpatient echocardiography showed an increase in the left ventricular ejection fraction to 54%. The presented case draws the attention of practicing physicians to the need to monitor the effectiveness and safety of antiarrhythmic therapy, especially in patients with organic myocardial damage.

1. Konstantopoulou A., Tsikrikas S., Asvestas D. et al. Mechanisms of drug-induced proarrhythmia in clinical practice. World J. Cardiol. 2013;5(6):175-85. DOI: 10.4330/wjc.v5.i6.175

2. Yakushin S.S., Nikulina N.N., Filippov E.V Results of the pilot part of the hospital registry of overdoses of cardiac drugs (GROZA): focus on drug-induced bradycardia. I.P. Pavlov Russian Medical and Biological Herald. 2020;28(2):153-163. (In Russian). DOI: 10.23888/PAVLOVJ2020282153-163

3. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N. Engl. J. Med. 1989;321(6):406-12. DOI: 10.1056/NEJM198908103210629

4. Sizova Zh.M., Shikh E.V., Beloborodova A.V., et al. Comparison of antiarrhythmic activity and safety of russian-made drugs containing lappaconitine hydrobromide. Kardiologiia. 2024;64(6):50-57. (In Russian). DOI: 10.18087/cardio.2024.6.n2667

5. Dolginina S.I., Duplyakov D.V. Allapinin's place in cardiac arrhythmia therapy. Cardiology: news, opinions, education. 2016;2(9):25-9. (In Russian).

6. Sokolov S.F., Golitsyn S.P., Malakhov V.I. et al. The effect of allapinin on the function of the atrioventricular conduction system of the heart. Cardiology. 1988;11:90-95. (In Russian).

7. Sokolov S.F., Alikhanov G.N., Golitsyn S.P., et al. Action of allapinin after a single intravenous administration in patients with chronic ventricular extrasystole. Cardiology. 1988;2:46-51. (In Russian).

8. Sokolov S.F. Results of a clinical study of the drug Allapinin and modern approaches to the treatment of patients with cardiac arrhythmia. Herald of Arrhythmology. 2011;64:60-70. (In Russian).

9. Kotlyarov A.A., Dmitrieva O.A., Mosina L.M., Karyakina T.N. Antiarrhythmic therapy of paroxysmal tachycardia and extrasystoles in patients with sinus node dysfunction. Klinicheskaya medirsina. 2012,9:57-59. (In Russian).

10. Kanorskiy S.G. Antiarrhythmic therapy in patients with paroxysmal and persistent forms of atrial fibrillation: definition of an achievable goal and assessment of available means. Cardiology. 2014;54(2):60-65. (In Russian).

11. Zamotaev Yu.N., Kremnev Yu.A., Grinenko N.A. et al. Evaluation of antiarrhythmic efficacy of the drug allapinin in patients with coronary heart disease with cardiac arrhythmias using daily ECG monitoring as an information control method. Russian Medical Journal. 2003;9:518-522 (In Russian).

12. Mrochek A.G., Gubar E.N. Efficiency of allapinin in patients with coronary heart disease with various heart rhythm disorders. Russian Journal of Cardiology. 2010;5(85):116-121 (In Russian).

13. Tarasov A.V. Safety issues of antiarrhythmic therapy. Consilium Medicum. 2014;16(10):44-49 (In Russian).

14. Dan G.A., Martinez-Rubio A., ESC Scientific Document Group. Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). Europace. 2018;20(5):731-732. DOI: 10.1093/europace/eux373

15. Salivonchik D.P. . Antiarrhythmic therapy: risk and benefit. Emergency cardiology and cardiovascular risks. 2018;2(2):438-449. (In Russian).

16. Tisdale J.E., Chung M.K., Campbell K.B. et al. American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association. Circulation. 2020;142(15):e214-e233. DOI: 10.1161/CIR.0000000000000905

17. Morganroth J. Horowitz L.N. Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram. Am. J. Cardiol. 1984;53:89-94.

18. Griffith L.. Platia E., Ord S,. Reid P. Persistent ventricular tachy-cardia/fibrillation: a possible adverse interaction between flecainide and class I antiarrhythmic drugs (abstract). J. Am. Coll. Cardiol. 1984;3:583

19. Al-Khatib S.M., Stevenson W.G., Ackerman M.J. et al. AHA/ ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018;138:272-391. DOI: 10.1161/CIR.0000000000000549

20. Budanova M.A., Chmelevsky M.P., Treshkur T.V., Tikhonenko V.M. Electrocardiographic criteria and algorithms for differential diagnostics of arrhythmias with wide QRS complexes. Bulletin of Arrhythmology. 2020;27(4):24-32. (In Russian). DOI: 10.35336/VA-2020-4-24-32

21. Brugada J., Katritsis D.G., Arbelo E. et al. ESC Scientific Document Group. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur. Heart J. 2020;41(5):655-720. DOI: 10.1093/eurheartj/ehz467

22. Pantlin P.G., Bober R.M., Bernard M.L. et al. Class 1C antiarrhythmic drugs in atrial fibrillation and coronary artery disease. J. Cardiovasc. Electrophysiol. 2020;31(3):607-611. DOI: 10.1111/jce.14335

23. Sinyaeva A.S., Filippov E.V. Molecular pathways of myocardial fibrosis progression. Therapy possibilities. Eruditio Juvenium. 2024;12(3):478-487. (In Russian). DOI:10.23888/HMJ2024123478-487

24. Sychev D.A., Ostroumov O.D., Kochetkov A.I. et al. Drug-Induced Diseases. M.: Prometheus, 2022 (In Russian.).

25. Khasaeva E.I., Deulina L.E. Side effects of drugs. StudNet. 2022;5(5):10. (In Russian).

26. Gurbanova A.A., Pereverzeva K.G., Yakushin S.S., Budanova I.V. Clinical case of development of ventricular tachycardia and myocardial infarction against the background of taking antiarrhythmic drugs. Rational Pharmacotherapy in Cardiology. 2023;19(3):264-269. (In Russian). DOI: 10.20996/1819-6446-2023-2914.

27. Sychev DA, Ostroumova OD, Pereverzev AP, et al. Drug-induced diseases: approaches to diagnosis, correction and prevention. Pharmacovigilance. Pharmateka. 2020;27(6):113-126. (In Russian). DOI: 10.18565/pharmateca.2020.6.113-126

28. Zeppenfeld K., Tfelt-Hansen J., de Riva M. et al. ESC Scientific Document Group. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur. Heart J. 2022;43(40):3997-4126. DOI: 10.1093/eurheartj/ehac262.

29. Zipes D.P., Camm A.J., Borggrefe M. et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Com. Europace. 2006;8:746-837

30. Turturiello D., Cappato R. The many NOs to the use of Class IC antiarrhythmics: weren't the guidelines too strict? Eur Heart J Suppl. 2022;24:147-153. DOI: 10.1093/eurheartjsupp/suac073

31. Pantlin P.G., Bober R.M., Bernard M.L. et al. Class 1C antiarrhythmic drugs in atrial fibrillation and coronary artery disease. J. Cardiovasc. Electrophysiol 2020;31:607-611. DOI: 10.1111/jce.14335

32. Plechev V.V., Zagidullin Sh.Z., Yunusov V.M., Zubareva I.G., Nikolaeva I.E. Preventive use of allapinin in patients with coronary artery disease in the perioperative period of coronary artery bypass grafting. Cardiology. 2013;53(8):34-39 (In Russian).